Search
Now showing items 1-3 of 3
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
(2014)
Abstract
BACKGROUND:
Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious ...
A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women.
(University of Nairobi, 2014-02)
BACKGROUND:
In HIV-1-infected women, CD4 count declines occur during pregnancy, which has been attributed to hemodilution. However, for women who have not initiated antiretroviral therapy, it is unclear if CD4 declines ...
Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.
(University of Nairobi, 2014)
BACKGROUND:
For women at risk of HIV-1, effective contraception and effective HIV-1 prevention are global priorities.
METHODOLOGY:
In a clinical trial of pre-exposure prophylaxis (PrEP) for HIV-1 prevention in ...